Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Pretty weak financial results growth rate 3.4% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (17.5%)
  • Dividend yield for the last twelve months 3.6%
  • Free cash flow yield 2.0% (LTM)
  • Share price is 6.5% higher than minimum and 33.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (10.1x vs
    )
  • For the last 3 months insiders bought company shares on $0.1 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-1.5%)88.39
year average price 110.68  


year start price 130.35 2024-04-02

max close price 132.96 2024-06-24

min close price 83.01 2025-02-14

current price 88.39 2025-04-01
Common stocks: 2 528 810 012

Dividend Yield:  3.6%
FCF Yield LTM: 2.0%
EV / LTM EBITDA: 10.1x
EV / EBITDA annualized: 11.7x
Target EV / EBITDA (hist percentile):
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 223 522
Net Debt ($m): 23 481
EV (Enterprise Value): 247 003
EBITDA LTM ($m): 24 435
EV / LTM EBITDA: 10.1x
Price to Book: 5.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-04-01businesswire.com

Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24

2025-04-01prnewswire.com

Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky

2025-03-31accessnewswire.com

Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Merck & Co., Inc.(MRK)

2025-03-31accessnewswire.com

Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK

2025-03-31prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

2025-03-30accessnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK

2025-03-30accessnewswire.com

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

2025-03-30accessnewswire.com

Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

2025-03-30globenewswire.com

ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

2025-03-30accessnewswire.com

MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data